News

A woman in Italy developed atypical hemolytic uremic syndrome (aHUS) as a result of a blood cancer, which resolved after the cancer was brought into remission, a case study shows. The report, “Marginal zone lymphoma with anti-factor H IgM and atypical hemolytic uremic syndrome successfully treated…

A 47-year-old man developed atypical hemolytic uremic syndrome (aHUS) after using cocaine, but ultimately recovered before his condition led to long-term kidney damage, according to a case report in Spain. While past reports have linked aHUS to cocaine use, such cases are uncommon. The man described in the report…

Inflammation of the pancreas, known as pancreatitis, can occur alongside the rare disease atypical hemolytic uremic syndrome (aHUS) — as a team of researchers from China highlighted in a new report outlining the case of a young woman found to have both conditions. The woman sought medical attention due…

Soliris (eculizumab) helped control atypical hemolytic uremic syndrome (aHUS) in a patient whose symptoms included seizures and signs of neurological damage, according to a case report. The researchers said the case points to “the importance of timely diagnosis and treatment of aHUS as well as the…

Soliris (eculizumab) is safe and effective for treating children with various types of hemolytic uremic syndrome (HUS), including atypical HUS (aHUS), according to a real-world study involving pediatric patients in Israel. In fact, more than half of the children with aHUS given Soliris in the study achieved a…

Plasma exchange therapy successfully managed atypical hemolytic uremic syndrome (aHUS) triggered by pancreas inflammation in a 72-year-old man, according to a case report from China. However, discontinuation of plasma exchange and a transition to hemodialysis — a treatment used to remove waste and excessive fluid from the blood when…

Plasma exchange therapy followed by treatment with Soliris (eculizumab) was effective at managing atypical hemolytic uremic syndrome (aHUS) in a boy in China. The case was described in the report, “Plasma exchange combined with eculizumab in the management of atypical hemolytic uremic in pediatric patients:…

Epysqli (eculizumab-aagh), a biosimilar of Soliris (eculizumab), is now available for patients in the U.S., according to an announcement from Samsung Bioepis and Teva Pharmaceuticals. The biosimilar is authorized to treat people with atypical hemolytic uremic syndrome (aHUS), as well as paroxysmal nocturnal hemoglobinuria, and…

A woman with lupus in her early 30s, who developed atypical hemolytic uremic syndrome (aHUS) after pregnancy, was not suspected of having the rare condition until five days after her baby’s birth, which resulted in her not receiving the correct treatment, according to a case report from researchers in…

COVID-19 was the likely trigger of atypical hemolytic uremic syndrome (aHUS) in a boy found to carry a mutation that reduced the levels of an immune protein called CD46, which may have increased his chance of developing the disease, according to a report from Iran. The boy first improved…